1 Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
2 Division of Molecular Oncology and Immunology, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
3 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway.
4 Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
5 Lausanne Branch, Ludwig Institute for Cancer Research, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
6 Center of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
7 NKI Proteomics facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
8 Department of Molecular Biosciences, University of Texas, Austin, TX, USA.
9 Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
10 Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, The Netherlands.
11 Division of Biochemistry, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
12 Division of Oncogenomics, Oncode institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. r.agami@nki.nl.
13 Erasmus MC, Department of Genetics, Rotterdam University, Rotterdam, The Netherlands. r.agami@nki.nl.